We are live on ! Find out more
RGEN icon

Repligen

174.73 USD
+6.73
4.01%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
174.00
-0.73
0.42%
1 day
4.01%
5 days
3.68%
1 month
3.37%
3 months
33.51%
6 months
51.79%
Year to date
6.32%
1 year
53.62%
5 years
-41.05%
10 years
428.52%
 

About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Employees: 2,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 54.5%
Neutral 45.5%
Negative 0%
Neutral
Business Wire
5 days ago
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Neutral
Seeking Alpha
6 days ago
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Positive
Zacks Investment Research
19 days ago
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Neutral
Zacks Investment Research
19 days ago
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Positive
Zacks Investment Research
20 days ago
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
5 Biotech Stocks Worth Adding to Your Portfolio Now
Neutral
GlobeNewsWire
20 days ago
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
Positive
24/7 Wall Street
21 days ago
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
Positive
Zacks Investment Research
1 month ago
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
Neutral
Seeking Alpha
1 month ago
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™